Visiongain Publishes Stents Market Report 2020-2030

23 July 2020

Visiongain has launched a new report Stents Market Report 2020-2030: Forecasts by Product (Peripheral, Coronary), by Peripheral Stents Type (Iliac Stents, Femoral-Popliteal Stents, Renal Stents, Carotid Stents, Neurovascular Stents, Gastrointestinal), by Coronary Stents Type (Bare Metal Stents, Drug Eluting Stents, Bioresorbable Stents), by Material (Metal, Polymers, Biomaterials), by End-user (Hospitals, Cardiac Centers), by Type (Balloon-Expandable Stents, Self-Expandable Stents). Plus Analysis of Leading Companies and Countries.

Global Stents market was valued at US $xx billion in 2019 and is projected to grow at a CARG of xx% during the forecast period to reach a market value of US$ xx billion by 2030. Visiongain anticipates that the North American region market holds the major share and is projected to grow at a CAGR of xx% to reach a market value of US $xx billion by 2030. The Asia-Pacific market was valued at US $xx billion in 2019 and is projected to grow at the highest CAGR of xx% during the forecast period to reach a market value of US $xx billion by 2030. The market in the European and MEA countries is expected to grow at a CAGR of xx% and xx% during the forecast period 2020-2030.

Rising Prevalence of Diseases Worldwide
The high and growing prevalence and incidence of diseases, especially coronary and peripheral artery diseases (PAD), which account for the majority of stents use, is increasing and stimulating the demand for stents. In Europe, the U.S. and Japan, cardiovascular diseases (CVD) are a leading cause of death. For instance, in Japan, one third of all deaths are attributed to heart diseases. In the U.S., CVD accounts for about 25% of total deaths.

Continuous Product and Technology Developments
Continuous significant product/technology advancements and developments have been made in the stents market in the past decade, and these advancements have been a major growth driver of this market. Manufacturers are continuously working on improving and developing products/technology to overcome key issues with stents implantation such as restenosis and thrombosis. The stents market has not only introduced a new generation of stents over time but has also improved technical specifications and developed wider application areas for stents. The slumping stents market is improving due to innovation, the continuous influx of new products and technologies that can compete with ever-increasing competition from alternative technologies and substitutes worldwide, and better health care outcomes.

Decline In Average Selling Prices
Increasing competition is continuously making the stents market more cost sensitive with time. In addition, current global economic conditions along with health care reforms are adding to the competitive pressure and changing market dynamics, leading to the continuous decline in average selling prices of stents such as bare-metal stents and drug-eluting stents, primarily in the cardiology space (which holds a majority share of the global stents market).

Key Players in the Stents Market
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• Terumo Corp
• Stentys SA
• MicroPort Scientific Corporation
• Becton Dickinson and Co
• InspireMD Inc
• Olympus Corp
• Taewoong Co., Ltd.

Visiongain believes that the stents market will register strong growth. This report examines in detail the market by product type, peripheral stents, coronary stents, type, material, end-user, by region, and as a whole, providing the reader with a thorough overview of the market to help identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.

The Global Stents Market 2020-2030 report will be of value to anyone who wants to better understand the stents market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the stent industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021


Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021